StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$12.00+0.69 (+6.10%)

Close on Nov 18, 2026Market cap $237.93MP/E –Yield –

Keros Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Keros Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $14.54M, down 93.7% year over year. For fiscal 2025 it was $243.86M. The highest annual figure on record is $243.86M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$243.86M–
FY2024Dec 31, 2024$0-100.0%
FY2023Dec 31, 2023$151.00K–
FY2022Dec 31, 2022$0-100.0%
FY2021Dec 31, 2021$20.10M–
FY2020Dec 31, 2020$0-100.0%
FY2019Dec 31, 2019$10.00M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$32.00K-100.0%
Q4 FY2025Dec 31, 2025$380.00K–
Q3 FY2025Sep 30, 2025$14.12M–
Q2 FY2025Jun 30, 2025$18.17M–
Q1 FY2025Mar 31, 2025$211.19M–
Q4 FY2024Dec 31, 2024$0-100.0%
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$0–
Q4 FY2023Dec 31, 2023$143.00K–
Q3 FY2023Sep 30, 2023$8.00K–
Q2 FY2023Jun 30, 2023$0–
Q1 FY2023Mar 31, 2023$0-100.0%
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0-100.0%
Q2 FY2022Jun 30, 2022$0–
Q4 FY2021Dec 31, 2021$20.00M–
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$100.00K–
Q4 FY2020Dec 31, 2020$0-100.0%
Q3 FY2020Sep 30, 2020$0-100.0%
Q2 FY2020Jun 30, 2020$0-100.0%
Q1 FY2020Mar 31, 2020$0-100.0%
Q4 FY2019Dec 31, 2019$2.50M–
Q3 FY2019Sep 30, 2019$2.50M–
Q2 FY2019Jun 30, 2019$2.50M–
Q1 FY2019Mar 31, 2019$2.50M–

More Keros Therapeutics figures

See a number that looks wrong?